A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells.
We conducted a phase I trial to determine the dose and schedule of paclitaxel, when given together with filgrastim, which would optimally promote mobilization of stem cells with tolerable toxicity. Dose escalation began at 275 mg/m2 3 h infusion. Dose-limiting neuropathy was observed at the 300 mg/m2 dose level. A second dose escalation was conducted utilizing 24 h infusion schedules, beginning at 225 mg/m2. Dose escalation was continued by 25 mg/m2 increments to 300 mg/m2, at which dose neuropathy was again dose-limiting. The recommended dose and schedule of paclitaxel for the purpose of mobilization of stem cells, when given together with filgrastim, are 275 mg/m2 as a 24 h infusion. The median stem cell yield after this dose of paclitaxel was 6.6 x 10(6) CD34+ cells/kg/apheresis (range 3.6 x 10(6)-7.7 x 10(6)).
Burtness
B A
BA
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520-8032, USA.
Psyrri
A
A
Rose
M
M
D'Andrea
E
E
Staugaard-Hahn
C
C
Henderson-Bakas
M
M
Clark
M B
MB
Mechanic
S
S
Krause
D
D
Snyder
E
E
Cooper
R B
RB
Abrantes
J
J
Corringham
R
R
Deisseroth
A
A
Cooper
D L
DL
D000328:Adult; D018952:Antigens, CD34; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D001772:Blood Cell Count; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000473:pathology; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*
D018952:Antigens, CD34; D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel